Vistagen to present positive fasedienol phase 3 data and positive ph80 phase 2a data at upcoming scientific conferences

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced the company will present at two upcoming scientific conferences in november. “vistagen's presentations highlight the significant progress we have made to advance new therapies to address urgent unmet patient needs,” said.
VTGN Ratings Summary
VTGN Quant Ranking